Septerna (SEPN) Net Cash Flow (2023 - 2026)
Septerna (SEPN) posted quarterly Net Cash Flow of -$49.1 million for Q1 2026, down 74.48% year-over-year from -$192.4 million in Q1 2025, and up 75.35% quarter-over-quarter from -$199.3 million in Q4 2025.
Septerna (SEPN) Net Cash Flow (2023 - 2026) Analysis & Trends
Septerna's Net Cash Flow history runs 4 years deep, the most recent figure standing at -$49.1 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 74.48% year-over-year to -$49.1 million; the TTM figure through Mar 2026 stood at -$138.4 million (down 357.55% YoY), while the FY2025 annual figure was -$117.5 million, down 178.47% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$49.1 million, up from -$199.3 million in the prior quarter.
- The five-year high for Net Cash Flow was $150.0 million in Q4 2024, with the low at -$199.3 million in Q4 2025.
- The 4-year median for Net Cash Flow is -$22.9 million (2024), against an average of -$10.2 million.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow jumped 1594.16% in 2024, then plunged 294.11% in 2025.
- Septerna's Net Cash Flow stood at -$10.0 million in 2023, then surged by 1594.16% to $150.0 million in 2024, then slumped by 232.89% to -$199.3 million in 2025, then jumped by 75.35% to -$49.1 million in 2026.
- Business Quant data shows SEPN's Net Cash Flow at -$49.1 million in Q1 2026, -$199.3 million in Q4 2025, and $130.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Septerna | 2.08 Bn | 2.08 Bn | - | 13.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.06 Mn |
| Jun 30, 2026 | 13.06 Mn |
| Mar 31, 2026 | -49.12 Mn |
| Mar 31, 2026 | -49.12 Mn |
| Dec 31, 2025 | -199.27 Mn |
| Dec 31, 2025 | -199.27 Mn |
| Sep 30, 2025 | 130.68 Mn |
| Sep 30, 2025 | 130.68 Mn |
| Jun 30, 2025 | -20.73 Mn |
| Jun 30, 2025 | -20.73 Mn |
| Mar 31, 2025 | -28.15 Mn |
| Mar 31, 2025 | -28.15 Mn |
| Dec 31, 2024 | 149.95 Mn |
| Dec 31, 2024 | 149.95 Mn |
| Sep 30, 2024 | -42.93 Mn |
| Sep 30, 2024 | -42.93 Mn |
| Jun 30, 2024 | -25.12 Mn |
| Jun 30, 2024 | -25.12 Mn |
| Mar 31, 2024 | -7.14 Mn |
| Mar 31, 2024 | -7.14 Mn |